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Abstract 
Background: Congenital hypothyroidism (CH) is one of the most common preventative evolutionary disorders 
in newborns and children, which, if not treated promptly, leads to mental retardation and developmental 
disorders.  
Objective: The purpose of this study was to assess the developmental status of 3 to 5-year-old children with 
congenital hypothyroidism treated with levothyroxine in Ardabil city in Northwest Iran.  
Methods: In a descriptive cross-sectional study, 78 infants (44 boys and 34 girls) with congenital hypothyroidism 
under treatment with levothyroxine who referred to Ardabil city health centers during 2013-2018 were evaluated 
by an Ages and Stages Questionnaire (ASQ) for their developmental status.  
Results: In total, 32 (41%) were impaired and 46 (59%) were healthy according to the ASQ. Of those, 11 
children (14.1%) had temporary congenital hypothyroidism. There was no significant difference in terms of 
height, weight, birth weight, maternal age, number of tests performed each year, average TSH (Thyroid-
stimulating Hormone) in the first year of treatment, gender, place of residence, education and parental 
relationship between two impaired and healthy children. There was a significant relation between number of 
visits by doctor (p=0.02), age at diagnosis (p=0.001) and age at treatment time (p=0.003), initial dose of 
levothyroxine (p=0.02) with developmental status of children based on ASQ results.  
Conclusion: According to the findings of this study, it can be concluded that neonatal screening is one of the 
most successful health-system programs in the country, and the detection and initiation of hypothyroidism in 
neonates as soon as possible leads to a reduction in developmental disorder in them. 
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Abbreviations / Acronyms: 
ASQ: Ages and Stages Questionnaire; CH: Congenital hypothyroidism; WHO: World Health Organization 
 
1. Introduction 
Thyroid hormones are one of the most important hormones involved in the development of the human nervous 
system (1, 2). Congenital hypothyroidism (CH) is one of the most common congenital endocrine abnormalities due 
to thyroid hormone deficiency and it is seen in both transient and constant forms. It is one of the most common 
causes of preventable mental retardation in children and its prevalence in some countries is one in every three to four 
thousand live births (3, 4). Removal of iodine from the bloodstream is the first essential step in the production of 
thyroid hormones by the thyroid gland. The most common cause of hypothyroidism worldwide is iodine deficiency, 
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and in places with sufficient iodine, other causes such as autoimmune diseases and iatrogenic are involved in the 
development of hypothyroidism (5). According to World Health Organization (WHO), about two million people 
have iodine poverty worldwide. Iodine deficiency is common in many mountainous regions as well as Central 
Africa, North Asia, and the interior region of South America. In areas with partial iodine deficiency, there was an 
increase in goiter prevalence and in areas with severe iodine deficiency there was an increase in the prevalence of 
hypothyroidism and cretinism or mental and developmental retardation. Children with cretinism are usually born in 
regions with iodine deficiency and mothers with iodine deficiency and thyroid hormone deficiency who are not 
treated with iodine or thyroid hormone. Adding iodine to salt, bread and other foods significantly reduces the 
incidence of cretinism (5). Over the past decades, many efforts have been made in developing - and underdeveloped 
countries to prevent and treat neurological disorders and mental retardation caused by hypothyroidism (6, 7). One 
way is to diagnose congenital hypothyroidism by routine neonatal screening in the first month of birth by measuring 
the levels of the thyroid hormones such as TSH and levothyroxine (T4). Up until 1970, before the emergence of the 
screening system, more than one-third of children with hypothyroidism had not been diagnosed at the appropriate 
time required and had severe mental and neurological disorders in the years following infancy. There is no cure and 
prevention at this stage of the disease, so, delay in diagnosis and treatment of hypothyroidism for 5 to 6 months 
reduces the level of intelligence to less than 70 (8-10). Therefore, early detection and treatment of hypothyroidism 
using T4 and determining its appropriate dose could prevent mental retardation in children with congenital 
Hypothyroidism (11).  
 
Furthermore, due to greater prevalence of congenital hypothyroidism in Iran compared with that of Europe and 
South America (1 per 1000 in Iran vs. 1 per 3000 in Europe vs. 1 per 5000 in South America) and also due to the 
importance of the developmental status of children, especially in children with congenital hypothyroidism, in 
addition to the lack of study of this topic in Iran, particularly in Ardabil, the purpose of this study was to investigate 
the developmental status of 3 to 5-year-old children with congenital hypothyroidism treated with levothyroxine in 
Ardabil city. 
 
2. Material and Methods  
2. 1. Study design 
This is a descriptive cross-sectional study carried out on 78 children aged 3 to 5 years with permanent and transient 
congenital hypothyroidism who referred to Ardabil city Health Centers and were treated with levothyroxine during 
2013-2018 in Ardabil, Iran. Exclusion criteria included anomalies affecting developmental function or symptoms of 
anomaly syndrome.  
 
2.2. Method of Data collection and ASQ measurement 
Data were collected by a checklist  containing clinical and demographic information of patients such as age, gender, 
place of residence, parental relationship, parental education  level, head circumference, birth weight and height, 
maternal age at delivery, time of diagnosis, disease and treatment initiation, number of referrals to doctor and results 
of follow-up. Ages and Stages Questionnaire (ASQ) assessed the developmental status of children by age and the 
questionnaire consisted of 30 questions with a score of 0-10 on the basis of five dimensions including 
communication, gross and delicate motions, and individual-social and problem solving which was used to assess 3 
to 5-year-old children's developmental status. A “Yes” answer received a score of 10, a “Sometimes” answer 
received a score of 5 and a “No” answer received a score of zero. Its total score was compared with the standard 
score, and children based on ASQ final scores were divided into two impaired and normal status groups (12). 
Standardization and validation of the ASQ developmental disorders screening tool was determined and approved in 
a study by Sajedi et al. in Tehran, by evaluating children of Tehran city 913). 
 
2.3. Statistical analysis  
Data were analyzed by descriptive statistics, t-test and Chi-square using IBM© SPSS© Statistics version 21 (IBM© 
Corp., Armonk, NY, USA). The significant level was set at 0.05. 
 
2.4. Ethical approve 
The results of this study was approved by Ardabil University of Medical Sciences ethical committee and registered 
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3. Results 
Of all studied children, 56.4% were male and the rest female. There were 71.8% from urban areas and the rest from 
rural areas. Based on ASQ results, 41% of children had impaired ASQ and of those 84.4% had permanent congenital 
hypothyroidism (Table 1). In all, 65.6% of children with impaired ASQ were boys, 62.5% from urban areas, 25% 
had familial history all of which, was not statistically significant (Table 1). There was no statistically significant 
difference between healthy and impaired children in terms of height, weight and head circumference and maternal 
age (Table 2). There was no significant difference between the number of tests performed and the mean of referrals 
to doctors in two ASQ groups in all ages and at all times (Table 3). The average of TSH in the newborns with 
impaired and healthy ASQ results had no significant difference at all times (Table 4). The results showed that there 
was no significant relationship between the developmental status of children and the age at diagnosis and treatment 
time (Table 5). There was significant difference between the dose of levothyroxine and ASQ results (Table 6). 
 
Table 1. The Developmental status of children by type of congenital hypothyroidism, 
demographic data and familial history of disease 
Variables  ASQ results p-value 
Impaired Normal 
n % n % 
Type of Congenital hypothyroidism Temporal  5 15.6 6 13 0.74 
Permanent  27 84.4 40 87 
Total  32 41 46 59 
Gender Girl 11 34.4  23 50  0.17 
Boy 21 65.6  23 50  
Residence place Urban 20 62.5  36  78.3  0.2 
Rural 12 37.5  10  21.7  
Familial 
history 
yes 8  25  15  32.6  0.32 
no 24  75  31  67.4  
Mother education 
level 
Under diploma 10 31.2 10 21.7  0.5 
Diploma 16 50  23 50  
Graduate 6 18.7  13  28.3  
Father education level Under diploma 4 12.5  5 10.9  0.6 
Diploma 18 56.3 21 45.6 
Graduate 10 31.2 20 43.5 
 
 
Table 2. Relation between ASQ with height, Weight, Head round in birth time and age of mother 
Variables ASQ results Mean±SD p-value 
Height (cm) Impaired 49.1±3.4 0.23 
Normal 94.2±2.07 
Total 94.85±2.7 
Weight (gm) Impaired 3076.6±756 0.35 
Normal 3223.9±560 
Total 3163.5±640 
Head round (cm) Impaired 36±2.5 0.89 
Normal 35.9±1.6 
Total 35.9±13 
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First year Impaired 11 27.5 4.63 0.96 4.64 0.86 
Normal 29 72.5 4.65 4.58 
Second 
year 
Impaired 11 27.5 3.90 0.04 3.64 0.07 
Normal 29 72.5 3.38 3.24 
Third year Impaired 11 27.5 3.45 0.48 3.08 0.75 
Normal 29 72.5 3.24 3.27 
Four 
years old 
First year Impaired 10 47.6 4.37 0.27 4.60 0.9 
Normal 11 52.4 4.63 4.64 
Second 
year 
Impaired 10 47.6 3.56 0.37 3.20 0.6 
Normal 11 52.4 3.39 3.36 
Third year Impaired 10 47.6 3.06 0.99 3.20 0.6 
Normal 11 52.4 3.06 3.36 
Fourth 
year 
Impaired 10 47.6 2.43 0.18 2.30 0.36 
Normal 11 52.4 2.70 2.54 
Five 
years old 
First year Impaired 9 60 3.77 0.12 3.78 0.11 
Normal 6 40 4.67 4.66 
Second 
year 
Impaired 9 60 2.89 0.24 2.89 0.35 
Normal 6 40 3.34 3.34 
Third year Impaired 9 60 2.56 0.63 2.89 0.64 
Normal 6 40 2.34 2.67 
Fourth 
year 
Impaired 9 60 2.45 0.08 2.23 0.06 
Normal 6 40 3.00 2.83 
Fifth year Impaired 9 60 1.89 0.34 2.12 0.78 
Normal 6 40 2.17 2.17 
 
Table 4. The developmental status of children by mean of TSH in first year of treatment 
Time of test ASQ results n % Mean Rank p-value 
Birth time Impaired 32  41  41.6  0.48  
Normal  46  59  38  
After three years Impaired 11  27.5 23  0.42  
Normal  29  72.5 19.55 
After four year Impaired 10  47.6 11.85  0.56  
Normal  11  52.4 10.23 
After five year Impaired 9  60  8.89  0.39  
Normal  6  40  6.67 
 
Table 5. Relation between developmental status with age at the diagnosis and after treatment 
Variables  ASQ results p-value 
Impaired Normal 
Age in diagnosis time (day) 50.2  32.1  0.001  
Age in treatment time (day) 48.5 33.3 0.003 
 
Table 6. The developmental status of children by dose of Levothyroxine (mg/kg) 
Levothyroxine ASQ results p-value 
Impaired Normal 
n % n % 
<8 22 28.2 19 24.5 0.02 
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4. Discussion  
Congenital hypothyroidism is the most common treatable congenital disease, which can lead to mental or growth 
retardation and delay in infant Neuromotor development in the absence of timely diagnosis, or incomplete treatment. 
In this study, 41% and 59% of patients had impaired and normal ASQ results respectively. According to the study 
by LaFranchi et al., the ASQ test is more sensitive and specific than other tests for measuring developmental 
disorders, and was similar to our study results (14). Marks et al., in their study, observed that ASQ testing more 
closely examines the developmental status of 3 to 6 months children (12). In line with the present study, the study by 
Namakin et al., showed that the average score of ASQ based on developmental indices in children with congenital 
hypothyroidism was significantly lower than in healthy children (13). In the Mozaffari et al. study, 17.2% of 
children had no ASQ quorum score and the relative risk of neuro developmental disorders was 1.4 which, compared 
with the results of the present study,  had a lower percentage of neuro developmental disorder and the reason for this 
may be the small sample size of the present study (14). 
 
Frezzato et al. in  their  study, showed  that  delayed  major  and  delicate  movements between  the  two  healthy  
and  levothyroxine  treated  groups  was often  associated  with  speech  delay (15). The study by Gejao, Komur et 
al., in line with the results of the present study, indicated a weakness in speech and communication skills in these 
children (16, 17). Soliman et al. in a study did not find any developmental disorders among children treated with 
levothyroxine, which was not in line our findings (18) 
 
In this study, a statistically significant relationship was found between ASQ test outcome and age at diagnosis and 
age at treatment initiation. Consistent with the results of this study, Pniewska-Siark et al., in their study, showed that 
early diagnosis and treatment of hypothyroidism had a good prognosis in the first two weeks of birth (19). In the 
study of Arenz et al., cognitive development, BMI and motive skills evaluated in children with persistent congenital 
hypothyroidism were treated with levothyroxine at 4 to15 days postpartum during preschool, and results showed 
similarities to those of other children (20). A study by Aijaz et al. showed that, earlier treatment with levothyroxine 
evolved neurological and brain development, which was similar to our study results (21). A study by Boileau et al. 
found that, the Intelligence Quotient (IQ) of children who were treated before 21 days of age was higher than those 
treated after this age (22). In this study, there was no statistically significant relationship between ASQ test results 
and initial dose of levothyroxine. Selva et al., in their study, found that the initiation of high dose levothyroxine 
treatment in the first two weeks of birth was not significantly different from the low dose, but showed a significant 
difference in intelligence (5). In the study of Boileau et al., no significant difference was found between IQ and 
Levothyroxine doses, which was not in line with the present study (22). In this study, no correlation was found 
between children's developmental indices with baseline Thyroid-stimulating Hormone (TSH) and TSH average in 
the first year. In a LaFranchi et al.’s study it was found that there was no significant difference between different 
doses of levothyroxine and its combination with triyodotironina on children's developmental status and motive skills 
(3). The findings of a Baysal et al.’s study showed that factors such as gender, socioeconomic status of the family, 
birth weight and duration of serum TSH normalization after treatment had no significant effect on the development 
of children (23). Similar to our study results, Razavi et al., in their study, showed that early diagnosis and treatment 
along with initial levothyroxine dose were most important factors of ASQ scores of children with CH. Higher dose 
of the levothyroxine is required at onset (24). 
 
5. Study limitations  
There are some limitations for this study such as lack of access to all the infants (by phone call or by interview), 
small sample size of study for better conclusion and discussion and also determining the impact of nutrition. 
 
6. Conclusions  
Based on the findings of this study, it can be concluded that neonatal screening is one of the most successful health 
programs in Iran, and early detection and initiation of hypothyroidism in neonates, could reduce the developmental 
abnormalities in these children. Given the potential impact of congenital hypothyroidism in later years, especially in 
their learning, it is necessary to follow this study up to school-age in these children. 
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